EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Genomic landscape and clinical characteristics of ERBB2/HER2 -mutated colorectal cancers

Muhammed Dogukan Aksu, Paola Zinser Peniche, Doga Kahramangil Baytar, Bhaghyasree Jambunathan, Yu Jen Alexander Jan, Ronan Hsieh, Shafia Rahman, John C Krauss, Christine M Veenstra iD, Ibrahim Halil Sahin iD

The Oncologist · 06.08.2026 · 31 (9)

DOI: 10.1093/oncolo/oyag302 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Oncologist, online erschienen am 31.07.2026. Verfasst von Muhammed Dogukan Aksu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Medical Oncology, Department of Oncology, Mayo Clinic, Rochester, MN, 55905, United States. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Erb-b2 Receptor Tyrosine Kinases. Die Arbeit nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Molecular underpinnings and clinical characteristics of ERBB2/HER2-mutated colorectal cancers (CRCs) remain poorly understood. We aimed to comprehensively characterize the genomic landscape and clinical features of ERBB2/HER2-mutated CRC and to compare them with those of ERBB2/HER2-amplified CRC. Patients and methods We analyzed cBioPortal data from 4348 CRC patients with available ERBB2/HER2 profiling. Clinicodemographic features, microsatellite instability (MSI), tumor mutational burden, and alterations in 94 cancer-associated genes were evaluated using chi-square/Fisher’s exact test, Kruskal–Wallis test, and hierarchical clustering.

Results

ERBB2/HER2 putative driver mutations were identified in 95 patients (2.2%), amplifications in 87 (2.0%), and wild-type status in 4166 (95.8%). In the overall cohort, ERBB2/HER2-mutated tumors demonstrated significant KRAS enrichment (50.5%) compared to wild-type (37.7%; P = .014) and amplified tumors (18.4%; P < .001), alongside MSI enrichment (37.2% vs 1.6%; P < .001), elevated tumor mutational burden, and right-sided predominance. ERBB2/HER2-mutated tumors also showed broad driver co-alterations largely reflecting their MSI background. In contrast, ERBB2/HER2-amplified tumors exhibited left-sided predominance, with microsatellite stable (MSS)-restricted analyses revealing selective mutual exclusivity with KRAS (Log2 OR = −1.58; q = 0.019) and TP53 co-occurrence (Log2 OR = 2.04; q = 0.019). Hierarchical clustering confirmed that mutated and amplified tumors consistently occupy separate clusters across anatomical sites.

Conclusion

ERBB2/HER2 mutations and amplifications represent molecularly and clinically distinct subgroups. ERBB2/HER2-mutated tumors are characterized by an MSI-enriched, hypermutated background with frequent concurrent KRAS alterations, whereas amplified tumors exhibit selective KRAS mutual exclusivity and TP53 co-occurrence. These exploratory findings support alteration-specific therapeutic strategies in CRC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colorectal NeoplasmsErb-b2 Receptor Tyrosine KinasesHumansMutationMicrosatellite InstabilityFemaleMaleAgedMiddle AgedGenomics

Stichwörter der Autor:innen

ERBB2/HER2coloncolorectal neoplasmsgenomicsmutationrectum

Substanzen

Erb-b2 Receptor Tyrosine KinasesERBB2 protein, human

Autor:innen und Institutionen

  • Division of Medical Oncology, Department of Oncology, Mayo Clinic, Rochester, MN, 55905, United States.
  • Department of Medicine, Division of Hematology and Oncology, University of Pittsburgh School of Medicine, Pittsburgh, PA, 15213, United States.
  • Division of Hematology and Oncology, Swedish Cancer Institute, Seattle, WA, 98104, United States.
  • Department of Internal Medicine, Division of Medical Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, OH, 432120, United States.
  • Division of Hematology and Oncology, University of Michigan Medical School, Ann Arbor, MI, 48109, United States.

ORCID-Profile: Christine M Veenstra, Ibrahim Halil Sahin

Zitieren

APA

Aksu, M. D., Peniche, P. Z., Baytar, D. K., Jambunathan, B., Jan, Y. J. A., Hsieh, R., Rahman, S., Krauss, J. C., Veenstra, C. M., & Sahin, I. H. (2026). Genomic landscape and clinical characteristics of ERBB2/HER2 -mutated colorectal cancers. The Oncologist, 31(9). https://doi.org/10.1093/oncolo/oyag302

Vancouver

Aksu MD, Peniche PZ, Baytar DK, Jambunathan B, Jan YJA, Hsieh R, et al. Genomic landscape and clinical characteristics of ERBB2/HER2 -mutated colorectal cancers. The Oncologist. 2026;31(9). doi:10.1093/oncolo/oyag302

BibTeX
@article{Aksu2026,
  author = {Aksu, Muhammed Dogukan and Peniche, Paola Zinser and Baytar, Doga Kahramangil and Jambunathan, Bhaghyasree and Jan, Yu Jen Alexander and Hsieh, Ronan and Rahman, Shafia and Krauss, John C and Veenstra, Christine M and Sahin, Ibrahim Halil},
  title = {Genomic landscape and clinical characteristics of ERBB2/HER2 -mutated colorectal cancers},
  journal = {The Oncologist},
  year = {2026},
  volume = {31},
  number = {9},
  doi = {10.1093/oncolo/oyag302}
}
Kostenlos starten →